行情

KRYS

KRYS

Krystal Biotech
NASDAQ

实时行情|Nasdaq Last Sale

62.64
+2.72
+4.54%
盘后: 62.64 0 0.00% 16:00 12/06 EST
开盘
60.28
昨收
59.92
最高
62.86
最低
58.92
成交量
8.16万
成交额
--
52周最高
65.90
52周最低
16.82
市值
10.84亿
市盈率(TTM)
-53.3651
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KRYS 新闻

  • The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission
  • Benzinga.1天前
  • Krystal Biotech, Inc. (KRYS) Shares March Higher, Can It Continue?
  • Zacks.3天前
  • The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
  • Benzinga.3天前
  • 欧洲央行的负利率政策面临各国财政部长的反对
  • 环球外汇网官网.3天前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
+0.32%

热门股票

名称
价格
涨跌幅

KRYS 简况

Krystal Biotech, Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Company's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Company's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness and dehydration.
展开

Webull提供Krystal Biotech Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。